source
- Priavoid's Alzheimer's pill PRI-002 fails Phase 2 trialGerman biotech startup Priavoid has been developing a small-molecule pill intended to break up amyloid protein clumps in the brains of Alzheimer's patients. The company recently reported results f…
- Marrow Therapeutics raises $173M to develop bone-marrow-targeted gene therapies for blood disordersMarrow Therapeutics announced a $173 million financing round, combining a $53 million Series A led by founder Scion Life Sciences and venBio with a $120 million Series B led by OrbiMed. The compan…